Pharmacotherapy of disruptive behaviours in children and adolescents with or without mental retardation

被引:0
|
作者
Hässler, F
Buchmann, J
Fegert, JM
机构
[1] Univ Rostock, Klin Kinder & Jugendpsychiat & Psychotherapie, D-18058 Rostock, Germany
[2] Univ Ulm, Klin Kinder & Jugendpsychiat Psychotherapie, Ulm, Germany
关键词
disruptive behaviour; psychopharmacotheropy; conventional neuroleptics; atypical neuroleptics;
D O I
暂无
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The quoted prevalence of disruptive behaviour among children and adolescents varies widely between 4 and 9 percent. Disruptive behaviour as well as self-injurious behaviour occurs in 12 to 36 percent of individuals with mental retardation who reside in institutionol settings. The principles of treatment are the some as for persons without mental retardation, but modification of techniques may be necessary according to the individual patient's developmental level, and especially communication skills. Psychopharmacologicol, psychotherapeutic and educational interventions should be coordinated within an overall treatment. There is some evidence that the conventional antipsychotic zuclopenthixol has any positive effect on destructive behaviour. Few studies have described the succesfull use of the atypical antipsychotic risperidone to control severe self-injurious behaviour and other behaviour problems in a variety of diagnoses. Anti-convulsants, antidepressants and anxiolytic medications may also find an important place in the treatment of some individuals with disruptive behaviour. Stimulants alone or in combination with a typical neuroleptics are also effective for aggression related behaviour. Both conventional and atypical neuroleptics effectively influence aggressive disruptive behaviour in children and adolescents with or without subaverage intelligence.
引用
收藏
页码:332 / +
页数:7
相关论文
共 50 条
  • [41] The efficacy of the ''snoezelen'' in the management of children with mental retardation who exhibit maladaptive behaviours
    Shapiro, M
    Parush, S
    Green, M
    Roth, D
    [J]. BRITISH JOURNAL OF DEVELOPMENTAL DISABILITIES, 1997, 43 (85): : 140 - 155
  • [42] Depressive and disruptive disorders and mental health service utilization in children and adolescents
    Wu, P
    Hoven, CW
    Bird, HR
    Moore, RE
    Cohen, P
    Alegria, M
    Dulcan, MK
    Goodman, SH
    Horwitz, SM
    Lichtman, JH
    Narrow, WE
    Rae, DS
    Regier, DA
    Roper, MT
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 1999, 38 (09): : 1081 - 1090
  • [43] Pharmacotherapy for Children and Adolescents
    Weber, Lutz T.
    [J]. DEUTSCHES ARZTEBLATT INTERNATIONAL, 2023, 120 (25): : 423 - 424
  • [44] PHARMACOTHERAPY FOR PATIENTS WITH MENTAL-RETARDATION AND MENTAL-ILLNESS
    BOSHES, RA
    [J]. PSYCHIATRIC ANNALS, 1987, 17 (09) : 627 - 632
  • [45] Separate and combined effects of methylphenidate and a behavioral intervention on disruptive behavior in children with mental retardation
    Blum, NJ
    Mauk, JE
    McComas, JJ
    Mace, FC
    [J]. JOURNAL OF APPLIED BEHAVIOR ANALYSIS, 1996, 29 (03) : 305 - 319
  • [46] Pharmacotherapy of Disruptive Behaviors in Children with Intellectual Disabilities
    Hodgins, Gabrielle E.
    Winsor, Kristen
    Barnhill, Jarrett
    [J]. PEDIATRIC DRUGS, 2022, 24 (05) : 465 - 482
  • [47] EXPECTATIONS AND SOCIAL INTERACTIONS OF CHILDREN WITH AND WITHOUT MENTAL-RETARDATION
    MILLER, CT
    CLARKE, RT
    MALCARNE, VL
    LOBATO, D
    FITZGERALD, MD
    BRAND, PA
    [J]. JOURNAL OF SPECIAL EDUCATION, 1991, 24 (04): : 454 - 472
  • [48] Self-reported fears in children with and without mental retardation
    Ramirez, SZ
    Kratochwill, TR
    [J]. MENTAL RETARDATION, 1997, 35 (02): : 83 - 92
  • [49] DEVELOPMENT OF THE FEAR SURVEY FOR CHILDREN WITH AND WITHOUT MENTAL-RETARDATION
    RAMIREZ, SZ
    KRATOCHWILL, TR
    [J]. BEHAVIORAL ASSESSMENT, 1990, 12 (04): : 457 - 470
  • [50] Pharmacotherapy of Disruptive Behaviors in Children with Intellectual Disabilities
    Gabrielle E. Hodgins
    Kristen Winsor
    Jarrett Barnhill
    [J]. Pediatric Drugs, 2022, 24 : 465 - 482